Generic Name and Formulations:
Erythromycin (as base) 250mg, 333mg, 500mg; e-c tabs.
Arbor Pharmaceuticals, LLC
- Crossed Cerebellar Diaschisis May Be Benign in Migraine With Aura
- Recall Issued for Clopidogrel Bottles
- Zecuity Migraine Patch No Longer Available
- Combination Hypertension Treatments
- Hypertension Treatments: ACE Inhibitors
- Opioids with Abuse Deterrent Properties
Indications for ERY-TAB:
Susceptible infections including upper and lower respiratory, skin and soft tissue, genitourinary, Legionnaires' disease, pertussis, listeriosis.
250mg every 6 hours, 500mg every 12 hours, or 333mg every 8 hours; max 4g/day; twice daily dosing max 1g/day. Legionnaires: 1–4g/day in divided doses.
30–50mg/kg/day in divided doses; max 100mg/kg/day.
Concomitant cisapride, pimozide.
Hepatic dysfunction. Myasthenia gravis. Pregnancy (Cat.B). Nursing mothers.
See Contraindications. May potentiate or be potentiated by drugs metabolized by CYP450 (eg, carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, disopyramide, bromocriptine, valproate). May potentiate warfarin, triazolam, midazolam, methylprednisolone, digoxin, theophylline, ergotamine. Avoid use with statins (rhabdomyolysis).
GI upset, abdominal pain, anorexia, hepatic dysfunction, rash, superinfection; pseudomembranous colitis, (rare).
250mg—30, 40, 100, 500; 333mg—30, 100, 500; 500mg—100
Neurology Advisor Articles
- FDA Approves Aimovig for Migraine Prevention
- Prediction Algorithm Stratifies ICH Patients at Risk for Hematoma Expansion
- Sports-Related Concussion Outcomes Predicted With Serum Neurofilament Light
- FDA: Lamotrigine Linked to Potentially Life-Threatening Adverse Reaction
- Psychological Therapies May Help Older Adults With Chronic Pain
- Amyloid Positivity Increases Risk for Cognitive Impairment in Dementia-Free Patients
- Valproic Acid-Related Adverse Fetal Outcomes May Be Linked to Placental Effects
- Risk of Dementia Up for Older Adults With Lowest Wealth
- Language Used in Medical Record Can Affect Patient Care
- Mortality in Alzheimer Disease Not Strongly Associated With Antipsychotics